Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FATE FT596 With Rituximab as Relapse Prevention in High Risk Patients After Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma

Next Previous
X
Search
Trial Profile

FATE FT596 With Rituximab as Relapse Prevention in High Risk Patients After Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FT 596 (Primary) ; Rituximab (Primary)
  • Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions

    • Most Recent Events

    • 09 Jul 2024 Status changed from active, no longer recruiting to completed.
    • 21 Feb 2023 Planned End Date changed from 1 Oct 2025 to 2 Feb 2024.
    • 21 Feb 2023 Status changed to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top